Nicholas Hoffman & Company LLC. lessened its position in Kenvue Inc. (NYSE:KVUE – Free Report) by 1.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 59,815 shares of the company’s stock after selling 915 shares during the quarter. Nicholas Hoffman & Company LLC.’s holdings in Kenvue were worth $1,384,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Leo Wealth LLC raised its holdings in Kenvue by 0.3% in the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock valued at $3,507,000 after acquiring an additional 481 shares during the last quarter. Massmutual Trust Co. FSB ADV grew its position in shares of Kenvue by 6.2% in the third quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock valued at $194,000 after purchasing an additional 492 shares in the last quarter. Wolff Wiese Magana LLC increased its holdings in shares of Kenvue by 0.7% in the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock valued at $1,781,000 after purchasing an additional 501 shares during the last quarter. Marathon Capital Management lifted its position in Kenvue by 0.3% during the second quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock worth $2,722,000 after buying an additional 514 shares in the last quarter. Finally, Manchester Capital Management LLC boosted its stake in Kenvue by 80.8% during the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after buying an additional 530 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
KVUE has been the subject of several analyst reports. Jefferies Financial Group began coverage on Kenvue in a report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 target price for the company. Royal Bank of Canada lowered shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price on the stock. in a report on Tuesday, September 24th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. UBS Group upped their price objective on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Finally, Bank of America raised their target price on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $22.64.
Kenvue Trading Down 0.4 %
KVUE opened at $22.78 on Wednesday. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $23.55. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.69. The business has a fifty day simple moving average of $22.46 and a 200-day simple moving average of $20.34. The firm has a market cap of $43.62 billion, a P/E ratio of 29.21, a P/E/G ratio of 3.00 and a beta of 1.40.
Kenvue (NYSE:KVUE – Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.04. The company had revenue of $4 billion during the quarter, compared to analysts’ expectations of $3.93 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. Kenvue’s revenue for the quarter was down .3% on a year-over-year basis. During the same period last year, the business posted $0.32 EPS. On average, equities analysts expect that Kenvue Inc. will post 1.08 earnings per share for the current year.
Kenvue Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be paid a $0.205 dividend. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 annualized dividend and a dividend yield of 3.60%. Kenvue’s dividend payout ratio (DPR) is 105.13%.
About Kenvue
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
- Five stocks we like better than Kenvue
- Why is the Ex-Dividend Date Significant to Investors?
- Financial Stocks Holding Firm Near Highs: 2 Key Players to Watch
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Upwork Fortifies Profitability Plan With Raised Q3 Forecasts
- What does consumer price index measure?
- 2 Small Modular Reactor Stocks Racing to Power AI Data Centers
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.